Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications

Psychedelics, known for their cultural and spiritual roles, are emerging as promising therapeutic agents by profoundly altering consciousness, emotional processing, mood, and neural plasticity. They modulate brain connectivity, particularly by enhancing functional connections between sensory areas while reducing connections in associative regions like the default mode network, thereby decreasing rigidity and increasing plasticity. The relaxed beliefs under psychedelics (REBUS) model and changes in cortico-striatal thalamo-cortical loops help explain these effects. Clinical trials of MDMA, psilocybin, and LSD show significant efficacy in treating treatment-resistant PTSD, depression, and anxiety with favorable safety profiles. However, linking molecular actions to clinical outcomes remains a critical gap needing further research.

Study at a glance

Abstract

Psychedelics, historically celebrated for their cultural and spiritual significance, have emerged as potential breakthrough therapeutic agents due to their profound effects on consciousness, emotional processing, mood, and neural plasticity. This review explores the mechanisms underlying psychedelics’ effects, focusing on their ability to modulate brain connectivity and neural circuit activity, including the default mode network (DMN), cortico-striatal thalamo-cortical (CSTC) loops, and the relaxed beliefs under psychedelics (REBUS) model. Advanced neuroimaging techniques reveal psychedelics’ capacity to enhance functional connectivity between sensory cerebral areas while reducing the connections between associative brain areas, decreasing the rigidity and rendering the brain more plastic and susceptible to external changings, offering insights into their therapeutic outcome. The most relevant clinical trials of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD) demonstrate significant efficacy in treating treatment-resistant psychiatric conditions such as post-traumatic stress disorder (PTSD), depression, and anxiety, with favorable safety profiles. Despite these advancements, critical gaps remain in linking psychedelics’ molecular actions to their clinical efficacy. This review highlights the need for further research to integrate mechanistic insights and optimize psychedelics as tools for both therapy and understanding human cognition.